Skip to main content

Table 2 Clinicopathological characteristics of patient samples and expression of NCAPG in LUAD

From: NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway

Clinical characteristics Number of cases (%)
Age (y)
 ≥ 65 160 (54.8)
 < 65 132 (45.2)
Sex
 Male 150 (51.4)
 Female 142 (48.6)
Clinical stage
 I 150 (51.4)
 II 72 (24.7)
 III 51 (17.5)
 IV 19 (6.5)
T classification
 T1 88 (30.1)
 T2 164 (56.2)
 T3 24 (8.2)
 T4 16 (5.5)
N classification
 N0 184 (63.0)
 N1 63 (21.6)
 N2 44 (15.1)
 N3 1 (0.3)
Metastasis
 No 273 (93.5)
 Yes 19 (6.5)
Expression of NCAPG
 Low expression 128 (43.8)
 High expression 164 (56.2)
  1. T for extent of the primary tumor; N for involvement of lymph nodes
  2. T1: Tumor ≤ 3 cm; T2: Tumor > 3 but ≤ 5 cm or tumor involving visceral pleura, main bronchus (not carina), atelectasis to hilum; T3: Tumor > 5 but ≤ 7 cm or invading chest wall, pericardium, phrenic nerve or or separate tumor nodule(s) in the same lobe; T4: Tumor > 7 cm or tumor invading: mediastinum, diaphragm, heart, great vessels, recurrent laryngeal nerve, carina, trachea, esophagus, spine or tumor nodule(s) in a different ipsilateral lobe
  3. N0: No regional node metastasis; N1: Metastasis in ipsilateral pulmonary or hilar nodes; N2: Metastasis in ipsilateral mediastinal/subcarinal nodes; N3: Metastasis in contralateral mediastinal/hilar, or suprclavicular nodes